Charles M. Baum - Jan 14, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
President,Founder,Head of R&D, Director
Signature
/s/ Vickie Reed, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Jan 14, 2022
Transactions value $
-$203,272
Form type
4
Date filed
1/18/2022, 07:32 PM
Previous filing
Jan 6, 2022
Next filing
May 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +25.5K +25.25% $0.00 127K Jan 14, 2022 Direct F1
transaction MRTX Common Stock Options Exercise $100K +3.7K +2.92% $27.00 130K Jan 18, 2022 Direct
transaction MRTX Common Stock Sale -$303K -2.52K -1.93% $120.48 128K Jan 18, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Employee Stock Option (Right to Buy) Award $0 +42.3K $0.00 42.3K Jan 14, 2022 Common Stock 42.3K $124.31 Direct F4
transaction MRTX Employee Stock Option (Right to Buy) Options Exercise $0 -3.7K -2.04% $0.00 178K Jan 18, 2022 Common Stock 3.7K $27.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.
F3 The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.19 to $120.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F4 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.